Do analysts rate TAK or SNY?

Sanofi has a consensus price target of $51.00, suggesting a potential upside of 13.28%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Sanofi 0 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.47

Does the media refer more to TAK or SNY?

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 3 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Sanofi's score of 0.25 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GSK or TAK?

GSK presently has a consensus target price of $53.00, suggesting a potential upside of 2.78%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 3 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.89 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, GSK or TAK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.43 $7.54B $3.85 13.39 Takeda Pharmaceutical $28.32B 1.75 $1.27B $0.39 40.01

Does the media prefer GSK or TAK?

In the previous week, GSK had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for GSK and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat GSK's score of 0.60 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ARGX or TAK?

argenex currently has a consensus price target of $1,019.50, suggesting a potential upside of 14.38%. Given argenex's stronger consensus rating and higher possible upside, equities analysts clearly believe argenex is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.92 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor ARGX or TAK?

In the previous week, argenex had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for argenex and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat argenex's score of 0.42 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or TEVA?

Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Teva Pharmaceutical Industries 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Do analysts rate RVMD or TAK?

Revolution Medicines presently has a consensus price target of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Revolution Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to RVMD or TAK?

In the previous week, Revolution Medicines had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for Revolution Medicines and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Revolution Medicines' score of 0.36 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Takeda Pharmaceutical (TAK) Competitors

$15.60 +0.15 (+0.98%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$15.51 -0.09 (-0.59%)

As of 06/5/2026 07:22 PM Eastern

Compare

TAK vs. SNY, GSK, ARGX, TEVA, and RVMD

Should you buy Takeda Pharmaceutical stock or one of its competitors? MarketBeat compares Takeda Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Takeda Pharmaceutical compare to Sanofi?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.75	$1.27B	$0.39	40.01
Sanofi	$49.35B	2.21	$8.84B	$3.58	12.58

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 3 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Sanofi's score of 0.25 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Sanofi has a net margin of 16.95% compared to Takeda Pharmaceutical's net margin of 4.31%. Sanofi's return on equity of 13.39% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Sanofi	16.95%	13.39%	7.58%

Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanofi has a consensus price target of $51.00, suggesting a potential upside of 13.28%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Summary

Sanofi beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.43	$7.54B	$3.85	13.39
Takeda Pharmaceutical	$28.32B	1.75	$1.27B	$0.39	40.01

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. GSK pays out 47.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, GSK had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for GSK and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat GSK's score of 0.60 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 4.31%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

GSK presently has a consensus target price of $53.00, suggesting a potential upside of 2.78%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.89
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

Summary

GSK beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to argenex?

argenex (NASDAQ:ARGX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, argenex had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for argenex and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat argenex's score of 0.42 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex currently has a consensus price target of $1,019.50, suggesting a potential upside of 14.38%. Given argenex's stronger consensus rating and higher possible upside, equities analysts clearly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 44.37% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

60.3% of argenex shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

argenex has higher earnings, but lower revenue than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.66B	11.89	$1.29B	$22.46	39.68
Takeda Pharmaceutical	$28.32B	1.75	$1.27B	$0.39	40.01

argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Summary

argenex beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Teva Pharmaceutical Industries had 26 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 29 mentions for Teva Pharmaceutical Industries and 3 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.16 beat Takeda Pharmaceutical's score of 0.80 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	22 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Takeda Pharmaceutical's net margin of 4.31%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.75	$1.27B	$0.39	40.01
Teva Pharmaceutical Industries	$17.35B	2.27	$1.41B	$1.33	25.72

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Takeda Pharmaceutical has a net margin of 4.31% compared to Revolution Medicines' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 11.07% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

Revolution Medicines presently has a consensus price target of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Revolution Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Takeda Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,739.75	-$1.13B	-$7.07	N/A
Takeda Pharmaceutical	$28.32B	1.75	$1.27B	$0.39	40.01

In the previous week, Revolution Medicines had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for Revolution Medicines and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Revolution Medicines' score of 0.36 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Revolution Medicines beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$49.65B	$2.96B	$6.66B	$23.06B
Dividend Yield	1.61%	1.70%	2.67%	4.10%
P/E Ratio	40.01	18.12	24.03	30.25
Price / Sales	1.75	292.63	518.10	22.07
Price / Cash	5.03	56.17	26.99	18.46
Price / Book	0.97	3.83	10.24	4.62
Net Income	$1.27B	$75.85M	$3.57B	$1.07B
7 Day Performance	-2.27%	-1.85%	-1.28%	-1.66%
1 Month Performance	-6.10%	-5.62%	1.38%	-1.07%
1 Year Performance	4.26%	14.98%	23.93%	21.20%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	3.5833 of 5 stars	$15.60 +1.0%	N/A	+4.3%	$49.65B	$28.32B	40.01	47,455
SNY Sanofi	4.2859 of 5 stars	$42.96 -1.6%	$51.00 +18.7%	-10.8%	$105.87B	$49.35B	12.00	74,846	News Coverage
GSK GSK	2.5269 of 5 stars	$49.23 -2.6%	$53.00 +7.6%	+25.1%	$102.56B	$43.07B	12.79	66,841	News Coverage Dividend Cut
ARGX argenex	3.6383 of 5 stars	$836.09 +0.0%	$1,019.50 +21.9%	+52.1%	$51.99B	$4.25B	37.23	1,863	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8513 of 5 stars	$34.51 -2.3%	$41.78 +21.1%	+92.6%	$40.61B	$17.35B	25.95	33,950	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. SNY, GSK, ARGX, TEVA, and RVMD

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Summary

How does Takeda Pharmaceutical compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. SNY, GSK, ARGX, TEVA, and RVMD

How does Takeda Pharmaceutical compare to Sanofi?

Which has higher valuation and earnings, TAK or SNY?

Does the media refer more to TAK or SNY?

Which has more volatility & risk, TAK or SNY?

Is TAK or SNY more profitable?

Is TAK or SNY a better dividend stock?

Do insiders and institutionals hold more shares of TAK or SNY?

Do analysts rate TAK or SNY?

Summary

How does Takeda Pharmaceutical compare to GSK?

Which has higher earnings & valuation, GSK or TAK?

Is GSK or TAK a better dividend stock?

Does the media prefer GSK or TAK?

Do institutionals and insiders hold more shares of GSK or TAK?

Is GSK or TAK more profitable?

Do analysts rate GSK or TAK?

Which has more volatility and risk, GSK or TAK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Does the media favor ARGX or TAK?

Do analysts prefer ARGX or TAK?

Is ARGX or TAK more profitable?

Do insiders and institutionals have more ownership in ARGX or TAK?

Which has better earnings & valuation, ARGX or TAK?

Which has more risk & volatility, ARGX or TAK?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Does the media prefer TAK or TEVA?

Do analysts prefer TAK or TEVA?

Is TAK or TEVA a better dividend stock?

Is TAK or TEVA more profitable?

Which has stronger valuation and earnings, TAK or TEVA?

Do institutionals & insiders hold more shares of TAK or TEVA?

Which has more risk and volatility, TAK or TEVA?

Summary

How does Takeda Pharmaceutical compare to Revolution Medicines?

Is RVMD or TAK more profitable?

Which has more risk & volatility, RVMD or TAK?

Do analysts rate RVMD or TAK?

Which has stronger valuation and earnings, RVMD or TAK?

Does the media refer more to RVMD or TAK?

Do institutionals & insiders have more ownership in RVMD or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools